Skip to main content

Day: November 8, 2024

Vera Therapeutics to Participate at Upcoming Investor Conferences

Written by Customer Service on . Posted in Public Companies.

BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details:Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1sWebcast: https://wsw.com/webcast/guggen/vera/1942294Date: Wednesday, November 13, 2024Time: 9:30am ESTLocation: Boston, MA7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside Chat and 1x1sWebcast: https://wsw.com/webcast/evercore44/vera/2364138Date: Thursday, December 5, 2024Time: 7:55am ESTLocation: Coral Gables, FLA...

Continue reading

ASII’s GlobeTopper Platform: The Numbers That Matter

Written by Customer Service on . Posted in Public Companies.

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) — Accredited Solutions, Inc. (OTC: ASII) (“Accredited Solutions” or the “Company”), the parent company of Diamond Creek Water, today shared key facts about its newly acquired GlobeTopper business, showing why this digital gift card company is set for strong growth. The Business in Simple Terms:GlobeTopper helps businesses send digital gift cards to their customers and employees Currently makes $37 million in yearly revenue Works with over 2,700 popular brands like Amazon, Target, and Starbucks Operates in 65 countries worldwide“Think of GlobeTopper as a digital gift card powerhouse,” said Eduardo Brito, CEO of Accredited Solutions. “When a large company wants to reward thousands of employees with holiday gift cards, they use our platform to make...

Continue reading

Oxford Lane Capital Corp. Provides October Net Asset Value Update

Written by Customer Service on . Posted in Public Companies.

GREENWICH, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) — Oxford Lane Capital Corp. (Nasdaq: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (the “Company”) today announced the following net asset value (“NAV”) estimate as of October 31, 2024.Management’s unaudited estimate of the range of the NAV per share of our common stock as of October 31, 2024, is between $4.82 and $4.92. This estimate is not a comprehensive statement of our financial condition or results for the month ended October 31, 2024. This estimate did not undergo the Company’s typical quarter-end financial closing procedures and was not approved by the Company’s board of directors. We advise you that our NAV per share for the quarter ending December 31, 2024 may differ materially from this estimate, which...

Continue reading

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Written by Customer Service on . Posted in Public Companies.

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers WILMETTE, Ill., Nov. 08, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced third quarter 2024 financial results and summarized recent developments. Recent Developments ALXN-1840 for Wilson disease – Late StageOn October 23, 2024, the Company entered into an exclusive license with Alexion, AstraZeneca Rare Disease whereby the Company gained worldwide rights to develop and commercialize ALXN-1840 (bis-choline tetrathiomolybdate). ALXN-1840 is a drug...

Continue reading

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Written by Customer Service on . Posted in Mergers And Acquisitions.

BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company’s offices in London, shareholders approved the Company’s issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. “I am thrilled to announce this important step toward finalization of the merger of our two companies,” said Samir Patel, MD, Akari’s Interim President & CEO. “With the...

Continue reading

NuVista Energy Ltd. Announces Strong Third Quarter 2024 Financial and Operating Results, LNG Agreement, 2025 Budget, and Enhanced Shareholder Return Strategy

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, Nov. 08, 2024 (GLOBE NEWSWIRE) — NuVista Energy Ltd. (“NuVista” or the “Company“) (TSX: NVA) is pleased to announce strong financial and operating results for the three and nine months ended September 30, 2024, and to provide an update on our operational performance. The quality and composition of our asset base consistently enables us to generate strong returns across commodity price cycles. Subsequent to the third quarter, our daily production has reached new record levels, as we continue to invest in new high-return wells and infrastructure projects to support our development plans. We also added LNG market access to our diversified natural gas portfolio and made significant progress on our return of capital to shareholders program through our normal course issuer bid (the “2024 NCIB”),...

Continue reading

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on . Posted in Public Companies.

Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the end of 2Q 2025 InflaRx pipeline highlighted at multiple medical congresses, including vilobelimab in COVID-19 and hidradenitis suppurativa (HS) and INF904 Phase 2a trial for INF904 expected to initiate by year-end 2024, with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of vilobelimab continues, with discussions ongoing and a CHMP opinion anticipated around mid-November Cash, cash equivalents and marketable securities of €62.0 million, expected to fund operations into 2026JENA, Germany, Nov. 08, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical...

Continue reading

Form 8.3 – [LEARNING TECHNOLOGIES GROUP PLC – 07 11 2024] – (CGWL)

Written by Customer Service on . Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LEARNING TECHNOLOGIES GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Fortrea Reports Third Quarter 2024 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

For the three months ended September 30, 2024, from continuing operations:Revenues of $674.9 million GAAP net loss of $(18.5) million Adjusted EBITDA of $64.2 million GAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectively Book-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 monthsDURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial results for the third quarter ended September 30, 2024. “We had a solid quarter of execution” said Tom Pike, chairman and CEO of Fortrea. “Our book-to-bill ratio for the quarter, as expected, is a nice mix of both large pharma and biotech awards. We have continued to make strong progress in the post-spin separation from our...

Continue reading

Prospect Capital Announces Financial Results for Fiscal September 2024 Quarter

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) — Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended September 30, 2024. “We are rightsizing our common shareholder distribution rate as we continue to execute our long-term income and total return strategy by rotating structured credit CLO equity and real estate investments into our core business of first lien senior secured middle market loans, including sometimes with selected equity co-investments,” said John Barry, Chairman and Chief Executive Officer of Prospect. “Our preferred shareholder cash distributions continue at the contractual rates of such distributions,” said Mr. Barry. “CLO equity and real estate investments have generated solid unlevered investment-level gross...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.